tiprankstipranks
Repligen Corp (RGEN)
NASDAQ:RGEN
US Market
Holding RGEN?
Track your performance easily

Repligen (RGEN) Earnings Dates, Call Summary & Reports

938 Followers

Earnings Data

Report Date
Feb 19, 2025
TBA Not Confirmed
Period Ending
2024 (Q4)
Consensus EPS Forecast
0.41
Last Year’s EPS
0.33
Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Nov 01, 2018
|
% Change Since: 15.05%
|
Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment with strong revenue and order growth, particularly in new modalities and CDMO performance. Regional growth was robust except for China, where challenges persist. While emerging biotech and clinical trial starts are a concern, the company's improved guidance and strategic initiatives indicate confidence moving forward.
Company Guidance
During Repligen Corporation's Q3 2024 earnings call, the company provided updated guidance for the full year with an expected revenue range of $630 million to $639 million, reflecting a midpoint of $634.5 million. This range incorporates approximately $7 million of incremental revenue due to a restatement. The company anticipates a 12% to 13% growth in non-COVID business in Q4, with recent acquisitions contributing to 3% of the total revenue growth. Adjusted gross margins are projected to be between 49.5% and 50.5%, while adjusted operating margins are expected to land between 12.5% and 13.5%. These figures have been updated to reflect the impact of restated financials. Additionally, Repligen forecasts an adjusted EBITDA margin of 17.5% to 18.5% and an adjusted diluted earnings per share between $1.50 and $1.58. The company noted strong year-over-year growth in North America and Asia, excluding China, and reported robust order growth, particularly in new modalities and consumables, setting a positive outlook for 2025.
Strong Third Quarter Revenue Growth
Repligen reported a 10% year-over-year sales growth and 6% order growth despite seasonal headwinds. Non-COVID sales were up 3% versus the last quarter, indicating strong market conditions.
Record Revenue in New Modalities
The company achieved a record revenue quarter for new modalities, with sales up more than 20% year-over-year and orders up low double digits compared to Q3 2023.
Improved CDMO Performance
CDMO revenue and orders grew approximately 20% year-over-year, recovering to 2022 levels. The business rebounded with orders up mid-teens over the last two quarters compared to the same period last year.
Strong Regional Growth Excluding China
North America and Asia (excluding China) showed strong sales growth, with Asia up more than 40% year-over-year.
Increased 2024 Financial Guidance
Repligen tightened its revenue guidance range to $630 million to $639 million for 2024, with an increase in gross margin guidance to 49.5% to 50.5%.
---

Repligen (RGEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

RGEN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 02, 20182018 (Q2)
- / 0.16
0.2-20.00% (-0.04)
Nov 01, 20182018 (Q3)
- / 0.20
0.1533.33% (+0.05)
Feb 21, 20192018 (Q4)
- / 0.21
0.25.00% (<+0.01)
May 09, 20192019 (Q1)
- / 0.28
0.1764.71% (+0.11)
Aug 01, 20192019 (Q2)
- / 0.31
0.1693.75% (+0.15)
Oct 31, 20192019 (Q3)
- / 0.26
0.230.00% (+0.06)
Feb 20, 20202019 (Q4)
- / 0.20
0.21-4.76% (>-0.01)
May 06, 20202020 (Q1)
- / 0.32
0.2814.29% (+0.04)
Jul 30, 20202020 (Q2)
- / 0.42
0.3135.48% (+0.11)
Nov 05, 20202020 (Q3)
- / 0.40
0.2653.85% (+0.14)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

RGEN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2024$139.51$148.59+6.51%
Jul 30, 2024$138.00$160.59+16.37%
May 01, 2024$164.20$158.36-3.56%
Feb 21, 2024$199.73$194.10-2.82%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Repligen Corp (RGEN) report earnings?
Repligen Corp (RGEN) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
    What is Repligen Corp (RGEN) earnings time?
    Repligen Corp (RGEN) earnings time is at Feb 19, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is RGEN EPS forecast?
          RGEN EPS forecast for the fiscal quarter 2024 (Q4) is 0.41.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis